Despite high disease burden, systemic treatment options for patients with atopic hand and/or foot dermatitis (H/F AD) are limited. To evaluate efficacy and safety of dupilumab in H/F AD using specific instruments for assessing disease severity on hands and feet. In this multicenter phase 3 trial, adults and adolescents with moderate-to-severe H/F AD were randomized to dupilumab monotherapy (regimen approved for generalized AD), or matched placebo. The primary endpoint was proportion of patients achieving Hand and Foot Investigator's Global Assessment score 0 or 1 at week 16. Secondary prespecified endpoints assessed the severity and extent of signs, symptom intensity (itch, pain), quality of life, and sleep. A total of 133 patients (adults = 106, adolescents = 27) were randomized to dupilumab (n = 67) or placebo (n = 66). At week 16, significantly more patients receiving dupilumab (n = 27) than placebo (n = 11) achieved Hand and Foot Investigator's Global Assessment score 0 or 1 (40.3% vs 16.7%; P = .003). All other prespecified endpoints were met. Safety was consistent with the known AD dupilumab profile. Short-term, 16-week treatment period. Dupilumab monotherapy resulted in significant improvements across different domains of H/F AD with acceptable safety, supporting dupilumab as a systemic treatment approach for this often difficult to treat condition.
Abstracts:Background: Pediatric atopic dermatitis (AD) can pose a significant financial burden to families. However, no studies exist that assess the impact of pediatric AD on health care access/affordability at the parental level. Objective: Explore the effects of childhood AD on parental access to health care and the socioeconomic factors that might exacerbate these problems. Methods:: The National Health Interview Survey was used to analyze 48,329,314 participants who answered the validated question on pediatric AD. Multivariable logistic regression analyses were performed to assess the association between pediatric AD and parental access to care. Results:: Parents of children with AD were more likely to have difficulty accessing prescription medications (aOR: 1.47; [95% CI 1.31–1.65]), follow-up care (1.36; [95% CI 1.17–1.57]), specialist care (aOR: 1.53; [95% CI 1.33–1.75]), and more likely to purchase medications from abroad (aOR: 1.35; [95% CI 1.09–1.67]) relative to their counterparts with children without AD. Within the AD cohort, uninsured or lower income participants had higher odds of facing these barriers to care. Conclusions:: Parents of children with AD are more likely to face barriers in health care access, and significant disparities exist based on sociodemographic characteristics.
1 September 2021 in Journal of the American Academy of Dermatology